retatrutide obesity trial results Eli Lilly infiltrates anti-obesity market as Phase III for begins Retatrutide, an Amazing Future for

4 new entrants to the $1B+ unicorn club, including Clarify Health and Transcarent

Recent studies among obese individuals without diabetes found poor 1-year persistence and adherence

LH and FSH will be suppressed during use

The rising prevalence of diabetes and obesity globally is a major public health concern and necessitates early treatment

Eli Lilly has developed tirzepatide, which adds activity of another incretin-like peptide, GIP, to the GLP-1 backbone

Use, Access and Affordability of GLP-1 Drugs KFFs latest Health Tracking Poll provides an update to last years poll measuring public use of GLP-1 agonists, a group of prescription drugs including name brands like Ozempic, Wegovy, Zepbound and others commonly prescribed for weight loss, the treatment of diabetes, reduction of cardiovascular disease risk, and some other chronic conditions 1